Posts tagged Chardan


Bullish Sentiment In Akari Therapeutics PLC (ADR) (AKTX) Reverses; Chardan Sees 63% Downside for the Stock

After a 200% rally in less than a month, Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) shares tumbled nearly …

Read more

Chardan Bullish on AveXis Inc (AVXS) Following Rival Spinraza Broad-Label Approval

Chardan analyst Gbola Amusa is placing his confidence behind AveXis Inc (NASDAQ:AVXS) even in light …

Read more

Chardan Heads to Sidelines on Arrowhead Pharmaceuticals Inc (ARWR) Following RNAi Program Discontinuations

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) are currently plummeting 62% in pre-market trading after yesterday’s announcement that …

Read more

Biotech Beat: Analysts Share Two Cents on Amicus Therapeutics, Inc. (FOLD) and Synergy Pharmaceuticals Inc (SGYP)

Analysts are offering their two cents on biotech firms Amicus Therapeutics, Inc. (NASDAQ:FOLD) and Synergy Pharmaceuticals …

Read more

Chardan Weighs in on Biotech Stocks Novavax, Inc. (NVAX) and Arrowhead Pharmaceuticals Inc (ARWR)

Chardan is divided when it comes to forecasts moving forward for biotech stocks Novavax, Inc. …

Read more

Analysts Speculate on Two Falling Biotech Stocks: Achillion Pharmaceuticals, Inc. (ACHN) and bluebird bio Inc (BLUE)

News from Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) and bluebird bio Inc (NASDAQ:BLUE) have sent biotech investors …

Read more

Analysts Weigh in on Three Rising Healthcare Stocks: Palatin Technologies, Inc. (PTN), Novocure Ltd (NVCR) and AveXis Inc (AVXS)

Healthcare stocks Palatin Technologies (NYSEMKT:PTN), Novocure Ltd (NASDAQ:NVCR), and AveXis Inc (NASDAQ:AVXS) are reaping the benefits …

Read more

Chardan Bearish on Arbutus Biopharma Corp (ABUS) Following Clinical Update

In a research report released Friday, Chardan analyst Madhu Kumar reiterated a Sell rating on …

Read more

Here’s Why Valuation Around Esperion Therapeutics Inc (ESPR) May Remain Depressed: Chardan

In a research report issued today, Chardan analyst Gbola Amusa maintained a Sell rating on …

Read more

Here’s Why Chardan Reduced Price Target For Uniqure NV (QURE)

In a research note issued today, Chardan analyst Gbola Amusa maintained a Buy rating on shares …

Read more